Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 μg), attenuated the intake suppression by i.p. liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. CONCLUSION: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109‐113).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 1×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Glucoreceptors Controlling Feeding and Blood Glucose: Location in the Hindbrain
Ritter, R. C., Slusser, P. G., & Stone, S. (1981) · Science · doi:10.1126/science.6264602 · Cited by 467 · cited 1×
“After a 7-d surgical recovery period, 3 ICV cannula placement was assessed by measurement of the sympathoadrenal-mediated hyperglycemic response to the cytoglucopenia induced by 5-thio-D-glucose (210 g in 2 l aCSF) (20).”
MethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Cited by
Items 201–300 of 345
Bernosky‐Smith, K. A., Stanger, D. B., Trujillo, A. J., Mitchell, L. R., España, R. A., & Bass, C. E. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.12.007 · Cited by 24
The Anorectic Effect of GLP-1 in Rats Is Nutrient Dependent
Sandoval, D., Barrera, J. G., Stefater, M. A., Sisley, S., Woods, S. C., D’Alessio, D. D., & Seeley, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051870 · Cited by 22
Brain delivery of proteins via their fatty acid and block copolymer modifications
Yi, X., & Kabanov, A. V. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.847098 · Cited by 24
Volcko, K. L., Carroll, Q. E., Brakey, D. J., & Daniels, D. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112910 · Cited by 31
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 21
“…activation of vagal afferents, through direct activation of central nervous system targets, and even through induction of nausea (Chaudhri et al., 2006; Hayes et al., 2011; Kanoski, Rupprecht, Fortin, De Jonghe, & Hayes, 2012; Parkinson et al., 2009; Rocca & Brubaker, 1999; Kanoski et al., 2011).”
BackgroundG Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
Physiologic and Neural Controls of Eating
Moran, T. H., & Ladenheim, E. E. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.009 · Cited by 28
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Potential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Jia, H., Wu, W., Lu, X., Zhang, J., He, C., & Zhang, H. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx112 · Cited by 20
“It is well known that GLP-1 reduces food consumption by eliciting satiety signals via the vagal afferents (Kanoski et al., 2011) or via blood perfusion into the hypothalamus in response”
BackgroundHomolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Antioxidants · doi:10.3390/antiox10071118 · Cited by 19
“introduced additional controls coadministered with intraperitoneal Ex-9 in doses likely exceeding those that could have effluxed after intracerebroventricular administration [117].”
BackgroundRuze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 20
Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents
Al Helaili, A., Park, S. J., & Beyak, M. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.045 · Cited by 17
Lee, J. Y., Park, T., Hong, E., Amatya, R., Park, K., Park, Y.-H., Min, K. A., Jin, M., Lee, S., Hwang, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120250 · Cited by 19
Greenwood, M. P., Greenwood, M., Bárez‐López, S., Hawkins, J. W., Short, K., Tatović, D., & Murphy, D. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101692 · Cited by 19
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., Koç, F., Stanton, C., Ross, R. P., & Šalković‐Petrišić, M. (2021) · Neuroendocrinology · doi:10.1159/000519988 · Cited by 19
Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice
Krass, M., Rünkorg, K., Vasar, E., & Volke, V. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00648.x · Cited by 18
“In fact, it has recently been shown that even the anorexigenic effect of peripherally administered liraglutide and exenatide is partly mediated by direct activation of GLP-1 receptor in the central nervous system (11).”
BackgroundAbtahi, S., Howell, E., Salvucci, J. T., Bastacky, J. M. R., Dunn, D. P., & Currie, P. J. (2018) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2018.10.008 · Cited by 20
Bi, Z., Wang, L., & Wang, W. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/161734 · Cited by 21
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Antagonization of central GLP-1R using exendin(9 (cid:0) 39) dampens food intake inhibition of i.p. administered liraglutide and exendin-4 [5], and liraglutide inhibition of food intake is attenuated in mice with neuronal loss of GLP-1R [6], hence emphasizing the relevance of central GLP-1R action…”
Fernandez-Cachon, M. L., Pedersen, S. L., Rigbolt, K. T. G., Zhang, C., Fabricius, K., Hansen, H. H., Elster, L., Fink, L. N., Schäfer, M., Rhee, N. A., et al. (2017) · Peptides · doi:10.1016/j.peptides.2017.12.024 · Cited by 18
Merkel, R., Moreno, A., Zhang, Y., Herman, R. J., Nathan, J. B., Zeb, S., Rahematpura, S., Stecyk, K. S., Milliken, B. T., Hayes, M. R., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.026 · Cited by 17
Self-citationFoll, C. L., & Lutz, T. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190034 · Cited by 27
Peripheral Signals Mediate the Beneficial Effects of Gastric Surgery in Obesity
Barja-Fernández, S., Folgueira, C., Castelao, C., Leis, R., Casanueva, F. F., & Seoane, L. M. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/560938 · Cited by 16
Hyde, K. M., Blonde, G. D., le Roux, C. W., & Spector, A. C. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.045 · Cited by 16
Cermakova, M., Pelantová, H., Neprašová, B., Šedivá, B., Maletínská, L., Kuneš, J., Tomášová, P., Železná, B., & Kuzma, M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00964 · Cited by 16
Crosstalk between alcohol use disorder and obesity: two sides of the same coin?
Leggio, L., Farokhnia, M., Kenny, P. J., Pepino, M. Y., & Simmons, W. K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03259-8 · Cited by 18
Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210974 · Cited by 21
“Ex-4 has been extensively studied in preclinical research due to its high binding affinity, prolonged half-life, and brain penetrance, making it especially suitable for investigating central mechanisms of feeding regulation [171,172].”
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Reidelberger, R. D., Haver, A. C., Anders, K., & Apenteng, B. A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2014 · Cited by 15
“In the experiment examining the effects of the high dose of PYY-(3–36) (50 pmol·kg (1)·min (1)), ANOVA demonstrated significant main effects of PYY-(3–36) on cumulative food intake at 3, 6, and 12 h [F(1,29) 7.”
BackgroundInfluentialGut hormones such as amylin and GLP-1 in the control of eating and energy expenditure
Lutz, T. A. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.4 · Cited by 20
Elfers, C. T., Simmons, J. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000338464 · Cited by 15
Lu, Z., Yeung, C. K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.09.003 · Cited by 14
“In addition, the availability of selective GLP-1 receptor antagonists, such as exendin (9–39) (Goke et al., 1993; Kanoski et al., 2011), has facilitated identification of the sites at which GLP-1 receptor agonists act.”
Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors
Keller, B. N., Hajnal, A. S., Browning, K. N., Arnold, A. C., & Silberman, Y. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.801825 · Cited by 18
Takagi, Y., Kinoshita, K., Ozaki, N., Seino, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138322 · Cited by 13
Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control
Ladenheim, E. E. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834ea723 · Cited by 13
Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13816 · Cited by 18
Jones, S., Hyde, A., & Davidson, T. L. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.001 · Cited by 18
Gao, L., Yu, S., Cipriani, A., Wu, S., Huang, Y., Zhang, Z., Yang, J., Sun, Y., Yang, Z., Chai, S., et al. (2019) · Aging and Disease · doi:10.14336/ad.2019.0303 · Cited by 13
Zhu, Y., Huang, J., Shen, T., & Yue, R. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/5070086 · Cited by 13
“*e existing diabetes treatment drugs GLP-1 agonists can play a role in suppressing appetite in diabetic patients by inhibiting the appetite center and delaying gastric emptying [2, 3].”
BackgroundPritchett, C. E., & Hajnal, A. S. (2011) · Obesity · doi:10.1038/oby.2011.342 · Cited by 15
“Previous research has shown that Exendin-4 administered peripherally reduces chow intake in hungry rats (22).”
InfluentialPharmacological Validation of Candidate Causal Sleep Genes Identified in an N2 Cross
Brunner, J. I., Gotter, A. L., Millstein, J., Garson, S. L., Binns, J., Fox, S. V., Savitz, A. T., Yang, H. S., Fitzpatrick, K., Zhou, L., et al. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.628426 · Cited by 14
“The GLP1R agonists, liraglutide (0.01 mg/kg, i.p.) and exendin-4 (0.003 mg/kg, i.p.), demonstrate anorectic effects in Sprague-Dawley rats within 1 hour of dosing (Kanoski et al., 2011).”
BackgroundInfluentialJust a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones
Roth, C. L., & Doyle, R. P. (2017) · Endocrine development · doi:10.1159/000475734 · Cited by 12
Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11
Self-citationGlucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“Likewise, in another study much higher doses of liraglutide and Ex-4 were needed to reduce food intake in rats after subdi-aphragmatic vagal deafferentation than in control rats (Kanoski et al. 2011).”
Nambu, T., Matsuda, Y., Matsuo, K., Kanai, Y., Yonemitsu, S., Muro, S., & Oki, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00242.x · Cited by 11
Kaineder, K., Birngruber, T., Rauter, G., Obermüller, B., Eichler, J., Münzker, J., Al-Zoughbi, W., Mautner, S., Torekov, S. S., Hartmann, B., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.98 · Cited by 15
Dávalos-Salas, M., Mariadason, J. M., Watt, M. J., & Montgomery, M. K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114091 · Cited by 13
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
In vitro cell cultures of Brunner’s glands from male mouse to study GLP-1 receptor function
Voetmann, L. M., Underwood, C. R., Rolin, B., Hansen, A. K., Kirk, R. K., Pyke, C., Knudsen, L. B., & Frederiksen, K. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00345.2021 · Cited by 10
Qiao, H., Ren, W.-N., Li, H.-Z., & Hou, Y.-X. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.03.002 · Cited by 9
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
“Favorable metabolic and inflammatory effects on several organ systems are testaments to the advantage of this class of therapies beyond weight loss and set them apart from prior AOMs with direct and indirect actions centrally and peripherally [29–36].”
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
“…the GLP-1R agonists exendin-4 and liraglutide when it was shown that the suppression of food intake that they cause upon systemic administration is prevented or attenuated when the GLP-1R antagonist exendin-9 is centrally administered in rats [7] and when central GLP-1Rs are deleted in mice [8].”
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 14
Self-citationGlucagon-Like Peptide-1 Receptors in the Gustatory Cortex Influence Food Intake
Dossat, A. M., Kokoska, M. M., Whitaker‐Fornek, J. R., Sniffen, S. E., Kulkarni, A. S., Levitt, E. S., & Wesson, D. W. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1668-22.2023 · Cited by 10
GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
Lee, S. P., Kuo, F. Y., Cheng, J., & Wu, M. C. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s207596 · Cited by 9
Wang, X., Zhao, X., Gu, Y., Zhu, X., Yin, T., Tang, Z., Yuan, J., Chen, W., Ouyang, R., Yao, L., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9783859 · Cited by 10
“The weight loss associated with GLP-1RA treatment has been attributed to delayed gastric emptying and appetite inhibition via the parasympathetic and/or hypothalamic pathways [30, 31].”
BackgroundVagal afferent controls of feeding: a possible role for gastrointestinal BDNF
Fox, E. A. (2012) · Clinical Autonomic Research · doi:10.1007/s10286-012-0170-x · Cited by 12
“Nevertheless, a representative group of studies that had such data or had single measures of FI or BW before, and two or more weeks after, SDA or capsaicin treatment were identified (SDA: [49, 51, 78, 80, 86, 88]; capsaicin: [16, 17, 40, 61, 85]).”
BackgroundHunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment
Cao, Y., & Tong, Q. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100569 · Cited by 10
Gu, Y., Wang, M., & Mao, Y. (2026) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2026.101247 · Cited by 9
A quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Zhou, Y. J., Xue, X., Guo, Y., Liu, H., Hou, Z., Zhou, C., Wang, N., Li, F., & Wang, Y. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211032133 · Cited by 10
“Although the blood–brain barrier (BBB) blocks most substances from taking in the brain, it is reported that EX-4 and liraglutide could enter the brain by crossing BBB and produce the receptor-mediated effects such as inhibiting feed consumption and weight gain in rodents.(37) Our result is consistent with the previous…”
ResultWang, P., Hill, T. A., Mitchell, J. M., Fitzsimmons, R. L., Xu, W., Loh, Z., Suen, J. Y., Lim, J., Iyer, A., & Fairlie, D. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00653 · Cited by 8
Steiner, A., Owen, B. M., Bauer, J. P., Seanez, L., Kwon, S., Biddinger, J. E., Huffman, R., Ayala, J. E., Nobis, W. P., & Lewis, A. S. (2022) · Hippocampus · doi:10.1002/hipo.23469 · Cited by 8
Overeating makes the gut grow fonder; new insights in gastrointestinal satiety signaling in obesity
Maljaars, J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d9fe0 · Cited by 11
“Long-acting GLP-1R agonists reduce food intake by acting on both peripheral and central GLP-1 receptor populations [8,9], leading to a small but significant loss of body weight in type 2 diabetics and in nondiabetic obese populations ( 2.”
BackgroundSekar, R., & Chow, B. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1353155 · Cited by 10
Lizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 9
Edvardsson, C. E., Vestlund, J., Ericson, M., & Jerlhag, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1439203 · Cited by 7
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists
Cook, T. M., Fuller, K. N. Z., & Sandoval, D. A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110269 · Cited by 7
Wilbs, J., Raavé, R., Boswinkel, M., Glendorf, T., Rodriguez, D. J., Fernandes, E. F. A., Heskamp, S., Bjørnsdottir, I., & Gustafsson, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02073 · Cited by 7
Glucagon-Like Peptide-1 and Its Implications in Obesity
Hurtado-Carneiro, V., Roncero, I., Blázquez, E., Álvarez, E., & Sanz, C. (2013) · InTech eBooks · doi:10.5772/54221 · Cited by 9
“The gastrointestinal tract responds to gut contents by secreting hormones, which can serve to inform the CNS of nutrient status.”
BackgroundInfluentialLiberini, C. G., Lhamo, R., Ghidewon, M. Y., Ling, T., Juntereal, N. A., Chen, J. C., Cao, A., Stein, L. M., & Hayes, M. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13591 · Cited by 8
Self-citationBarilar, J. O., Knezović, A., Homolak, J., Perhoč, A. B., & Šalković‐Petrišić, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010548 · Cited by 6
“They introduced another group that received an intraperitoneal GLP-1R inhibitor in doses that could have effluxed after icv injection and concluded that this ip treatment did not significantly attenuate intake suppression by ip delivery of agonists (the icv inhibitor antagonized peripherally administered liraglutide a…”
BackgroundMethodInfluentialAnesten, F., Mishra, D., Gasull, A. D., Engström, L., Bellman, J., Pálsdóttir, V., Zhang, F., Trapp, S., Skibicka, K. P., POUTANEN, M. H., et al. (2019) · Neuroendocrinology · doi:10.1159/000499693 · Cited by 8
Wright, F., & Rodgers, R. J. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3507-4 · Cited by 7
“Animals were handled regularly during routine husbandry and were thoroughly habituated to all experimental procedures prior to drug testing.”
BackgroundMethodResultInfluentialAmeer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
Merchant, W., Tinajero, A., KHAN, A. R., Chu, Y., Saleh, S., Tasabehji, D., Morgan, D. A., Williams, K. W., Rahmouni, K., Mokadem, M., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00452.2025 · Cited by 4
Knakker, B., Inkeller, J., Kovács, P., Lendvai, B., & Hernádi, I. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01981-5 · Cited by 6
“In addition, Ex also penetrates the blood-brain barrier and acts on central GLP-1Rs [19].”
BackgroundNonogaki, K., & Suzuki, M. (2013) · ISRN Endocrinology · doi:10.1155/2013/184753 · Cited by 7
“Second, the GLP1Rs in the afferent vagal nerve terminals could contribute to the liraglutide-mediated suppression of plasma active and des-acyl ghrelin levels because liraglutide stimulates the vagal afferents and the CNS, leading to satiety [16].”
BackgroundLu, K., Chen, X., Yan, J., Li, X., Huang, C., Wan, Q., Deng, X., & Zou, Q. (2018) · Obesity Facts · doi:10.1159/000486316 · Cited by 6
Jiang, Y., Cui, S., Zhang, R., Zhao, X., Yao, L., Ouyang, R., Chen, W., Zhou, R., Zhao, X., Tang, Z., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01107-w · Cited by 5
Treatment of obesity: bariatric surgery
Neff, K., Ferrannini, E., & le Roux, C. W. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch34 · Cited by 5
Gao, C., Geneve, I. C., Rodriguez-Gonzalez, S., Li, C., McElhern, K., Reitman, M. L., Lutas, A., & Krashes, M. J. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01534-8 · Cited by 10
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
“…by surgical or chemical methods, has been shown to block the appetite-suppressing effects of peripheral GLP-1 in rodent models (Abbott et al., 2005; Kanoski et al., 2011; Labouesse et al., 2012; Brierley and de Lartigue, 2022), underscoring the essential role of these neural connections in…”
Galsgaard, K. D., Modvig, I. M., & Holst, J. J. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241062 · Cited by 4
Gündüz, M. K., Kaymak, G., Kanbur, E., Berikten, D., & Şener, H. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105479 · Cited by 4
Renner, É., Dóra, F., Oszwald, E., Dobolyi, Á., & Palkovits, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415945 · Cited by 5
“, by inducing insulin secretion from beta cells of the pancreas, and central nervous system GLP-1Rs contribute to the beneficial actions of GLP-1R agonists [24,26–28] including the demonstration that the food intake reducing effect of GLP-1R agonists are blunted by central infusion of GLP-1R antagonists [29].”
BackgroundGLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
Morais, T., Pereira, S. S., Andrade, S., Neves, D., Guimarães, M., Nora, M. C., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2023) · Biomedicines · doi:10.3390/biomedicines11051322 · Cited by 4
“These effects seem to be partially mediated via the vagus nerve, given that vagotomy was previously reported to blunt the anorectic effects of GLP-1 [2], despite other GLP-1 effects that could be mediated by vagal independent mechanisms as well [20].”
BackgroundNakanishi, S., Hirukawa, H., Shimoda, M., Tatsumi, F., Kohara, K., Obata, A., Okauchi, S., Sanada, J., Fushimi, Y., Mashiko, A., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s252673 · Cited by 4
Sridhar, A., Khan, D., Flatt, P. R., Moffett, R. C., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171093 · Cited by 6
“Effects on body weight appeared to be at least partly related to inhibition of appetite in both treatment groups, that is certainly characteristic of GLP-1R agonism [27,28].”
Türkkahraman, D., Tekin, S., Güllü, M., & Aykal, G. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2023.2023-7-7 · Cited by 4
Morais, T., Patrício, B. G., Pereira, S. S., Andrade, S., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28719 · Cited by 5
Horn, C. C., Murat, C., Rosazza, M. R., & Still, L. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.057 · Cited by 4
“These incretin factors might act on vagal afferent fibers or directly on the brain (e.g., Kanoski et al., 2011).”
O'Brien, R., Buckley, M. M., & O’Malley, D. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14160 · Cited by 6
Lateral Septum as a Key Integrative Regulator of Feeding: Role of the GLP ‐1/ GLP ‐ 1R System
Dib, T., Covarrubias, M. J., Escobar, A. P., Renard, G. M., Bravo, J. A., & Sotomayor‐Zárate, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70301 · Cited by 3
“Beyond its role in glycemic regulation, GLP-1 receptor agonists (GLP-1RAs) promote weight loss in individuals with diabetes (Brown et al. 2018), an effect largely attributed to the peptide anorexigenic properties, which involve both central and peripheral mechanisms (Kanoski et al. 2016, 2011).”
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Self-citationGao, H., Zhao, Q., Li, K., Qin, F., Yin, X., Lu, Z., Song, Z., Wu, Y., Shen, Y., Pan, Y., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112454 · Cited by 3
Lv, P., Li, H., Li, X., Wang, X., Yu, J., & Gong, Y. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00217.2023 · Cited by 5
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“Functioning as both an anorexigenic neuropeptide and incretin hormone [97,108–113], GLP-1 interacts with GLP-1R on vagal afferent neurons [78,80,114–116], transmitting satiety signals to the nucleus of the solitary tract and the hypothalamus [108–112].”
Lu, X., Harada, N., Yasuda, T., Ikeguchi, E., Kobayashi, D., Denda, M., Seno, Y., Yamane, S., Yabe, D., Otaka, A., et al. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0026 · Cited by 2
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Metadata
- Authors
- Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R.
- Affiliations
- University of Pennsylvania (US)
- ETH Zurich (CH)
- Corresponding author
- Kanoski, Scott E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-06-21
- Volume
- 152
- Issue
- 8
- Pages
- 3103-3112
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3138234
- OpenAlex
- W1965072462
- Cited by
- 347
- References
- 51
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 16 · 2022: 18 · 2021: 30 · 2020: 23 · 2019: 26 · 2018: 19 · 2017: 21 · 2016: 27 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 23
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (DK21397, DK089752)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK089752, DK085435, R01DK021397, F32DK089752, K01DK085435, DK 21397, R56DK021397)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, exendin-4, exendin-9-39, feeding inhibition, anorectic effect, vagal afferents, intracerebroventricular administration, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Appetite Depressants, Body Weight, Brain, Calcitonin, Eating, Male, Peptide Fragments, Peptides, Vagus Nerve, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.